Association of serum fetuin-A levels with mortality in dialysis patients
Association of serum fetuin-A levels with mortality in dialysis patients
复制标题
DOI：
10.1038/sj.ki.5002178
复制
发表时间：
2007-07-01
影响因子：
19.6
通讯作者：
Dekker, F. W.
中科院分区：
文献类型：
--
作者：
Hermans, M. M. H.;Brandenburg, V.;Dekker, F. W.
钙化性动脉粥样硬化是一个由钙化抑制剂和诱导剂控制的主动过程。胎球蛋白-A是一种急性期糖蛋白，是羟磷灰石形成的更强大的循环抑制剂之一。启动了一项前瞻性多中心队列研究，包括血液透析（HD）和腹膜透析（PD）患者，以评价血清胎球蛋白A水平与心血管（CV）和非CV死亡率的相关性。血清胎球蛋白A浓度增加0.1 g/l与全因死亡率显著降低13%相关。非CV死亡率显著降低17%，CV死亡率几乎显著降低。胎球蛋白A与死亡率的相关性在HD和PD患者中相当，即使校正了包括但不限于年龄、性别、原发性肾脏疾病、C反应蛋白水平和营养状况等因素。我们的结论是，血清胎球蛋白-A浓度可能是透析患者死亡率的一般预测因子。
Calcifying atherosclerosis is an active process, which is controlled by calcification inhibitors and inducers. Fetuin-A, an acute phase glycoprotein, is one of the more powerful circulating inhibitors of hydroxyapatite formation. A prospective multicenter cohort study was initiated to include both hemodialysis (HD) and peritoneal dialysis (PD) patients in an evaluation of the association of serum fetuin-A levels with both cardiovascular (CV) and non-CV mortality. An increase in the serum fetuin-A concentration of 0.1 g/l was associated with a significant reduction in all-cause mortality of 13%. There was a significant 17% reduction in non-CV mortality and a near significant reduction in CV mortality. This association of fetuin-A and mortality rates was comparable in both HD and PD patients even when corrected for factors, including but not limited to age, gender, primary kidney disease, C-reactive protein levels, and nutritional status. We conclude that serum fetuin-A concentrations may be a general predictor of mortality in dialysis patients.